A
Price
$138.57
Change
-$1.17 (-0.84%)
Updated
Jul 24 closing price
Capitalization
39.14B
24 days until earnings call
Intraday BUY SELL Signals
DHR
Price
$191.50
Change
-$1.00 (-0.52%)
Updated
Jul 24 closing price
Capitalization
134.62B
94 days until earnings call
Intraday BUY SELL Signals
TMO
Price
$568.26
Change
-$4.06 (-0.71%)
Updated
Jul 24 closing price
Capitalization
211.18B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

A or DHR or TMO

A vs DHR vs TMO Comparison Chart in %
View a ticker or compare two or three
Jul 20, 2026

Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher Corporation (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison

Key Takeaways

  • Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) operate in the life sciences tools and diagnostics sector, with overlapping exposure to healthcare research and biopharma spending.
  • Recent market activity shows mixed performance across the group, influenced by broader economic sensitivity in capital equipment purchases and upcoming earnings reports.
  • TMO reported first-quarter 2026 revenue growth of 6% to $11.01 billion, beating estimates, with its second-quarter results scheduled for release on July 23, 2026.
  • Valuation multiples and growth trajectories differ, with each company exhibiting distinct sensitivities to M&A (mergers and acquisitions) activity and organic demand trends.
  • Sector-wide sentiment remains tied to pharmaceutical R&D budgets and regulatory environments, creating relative performance contrasts among the three.
  • Market positioning highlights trade-offs in scale, diversification, and end-market exposure that investors evaluate when comparing the names.

Introduction

Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) represent established players in the life sciences and analytical instrumentation space. These stocks attract attention from institutional investors, sector specialists, and traders monitoring healthcare supply chains and research spending cycles. The comparison provides a framework for assessing relative performance, business model differences, and positioning within a capital-intensive industry. Market participants seeking to understand sector dynamics, valuation contrasts, and recent momentum often review such peer groups to inform portfolio construction or tactical allocation decisions.

Agilent Technologies (A) Overview and Recent Performance

Agilent Technologies (A) provides analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has reflected broader sector volatility tied to capital spending patterns among research institutions and biopharma clients. Performance has been influenced by ongoing demand for its chromatography and mass spectrometry platforms, alongside sensitivity to macroeconomic factors affecting laboratory budgets. Sentiment has remained measured as investors monitor order trends and integration of recent product launches within the company's core segments.

Danaher Corporation (DHR) Overview and Recent Performance

Danaher Corporation (DHR) operates a diversified portfolio that includes life sciences, diagnostics, and environmental solutions through its Danaher Business System operating model. Recent market activity has shown the shares responding to shifts in healthcare utilization and instrumentation demand, with particular attention to its bioprocessing and diagnostics franchises. Performance in recent weeks has been shaped by M&A (mergers and acquisitions) execution and organic growth in key verticals, amid a backdrop of cautious capital deployment by customers. Market observers note the company's scale as a factor in relative stability during periods of sector rotation.

Thermo Fisher Scientific (TMO) Overview and Recent Performance

Thermo Fisher Scientific (TMO) delivers a broad range of life sciences tools, diagnostics, and laboratory services, serving academic, biopharma, and clinical customers. In recent weeks, the stock has traded in a range following its first-quarter 2026 results, which showed revenue rising 6% to $11.01 billion and adjusted earnings per share (EPS) increasing 6% to $5.44. The company is scheduled to report second-quarter results on July 23, 2026, keeping investor focus on organic growth trends and margin dynamics. Broader market activity reflects ongoing evaluation of its scale advantages and exposure to research funding cycles.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance statistics tailored to current market conditions. Only those demonstrating strong suitability and historical metrics earn placement in the trending section. Available bots span a wide range of win rates, drawdowns, and return profiles, allowing users to compare options across different trading styles. The resource provides transparent statistics to help evaluate fit for individual preferences. Review the Trending AI Robots page for the latest selections.

Head-to-Head Comparison

Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) share exposure to life sciences research and diagnostics yet differ in business models and growth drivers. Agilent (A) emphasizes precision analytical tools with higher sensitivity to laboratory capital budgets, while Danaher (DHR) leverages a diversified operating system across multiple end markets, offering potential ballast during sector-specific slowdowns. Thermo Fisher (TMO) benefits from greater scale and integrated offerings, which can support steadier revenue visibility but also heighten valuation sensitivity to earnings beats or misses. Recent momentum has varied, with TMO’s reported first-quarter results providing a near-term reference point amid upcoming updates. Risk factors include common sector exposures to R&D spending fluctuations and regulatory changes, offset by differing degrees of geographic and product diversification. Market sentiment reflects ongoing assessment of these trade-offs in valuation multiples and positioning relative to peers.

Tickeron AI Verdict

Based on observable factors such as trend consistency, earnings visibility, and relative sector positioning in recent market activity, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term characteristics to Thermo Fisher Scientific (TMO). This assessment incorporates its reported first-quarter results and scale advantages, though outcomes remain subject to broader market variables and the upcoming earnings release. The models emphasize probabilistic evaluation rather than deterministic forecasts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2026
Stock price -- (A: $138.57DHR: $191.50TMO: $568.26)
Brand notoriety: A, DHR and TMO are all not notable
The three companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 61%, DHR: 135%, TMO: 126%
Market capitalization -- A: $39.14B, DHR: $134.62B, TMO: $211.18B
$A is valued at $39.14B, while DHR has a market capitalization of $134.62B, and TMO's market capitalization is $211.18B. The market cap for tickers in this @Medical Specialties ranges from $3.82T to $0. The average market capitalization across the @Medical Specialties industry is $17.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).

  • A’s FA Score: 2 green, 3 red.
  • DHR’s FA Score: 1 green, 4 red.
  • TMO’s FA Score: 1 green, 4 red.
According to our system of comparison, A and TMO are a better buy in the long-term than DHR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 3 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).

  • A’s TA Score: 3 bullish, 3 bearish.
  • DHR’s TA Score: 4 bullish, 5 bearish.
  • TMO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TMO is a better buy in the short-term than A, which in turn is a better option than DHR.

Price Growth

A (@Medical Specialties) experienced а +5.41% price change this week, while DHR (@Medical Specialties) price change was -6.05% , and TMO (@Medical Specialties) price fluctuated +6.72% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.

Reported Earning Dates

A is expected to report earnings on Aug 18, 2026.

DHR is expected to report earnings on Oct 27, 2026.

TMO is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Medical Specialties (-1.55% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TMO($211B) has a higher market cap than DHR($135B) and A($39.1B). DHR has higher P/E ratio than TMO and A: DHR (34.14) vs TMO (30.58) and A (27.83). A YTD gains are higher at: 2.449 vs. TMO (-1.736) and DHR (-15.994). TMO has higher annual earnings (EBITDA): 11.7B vs. DHR (7.08B) and A (1.96B). A has less debt than DHR and TMO: A (3.36B) vs DHR (18.5B) and TMO (43.2B). TMO has higher revenues than DHR and A: TMO (45.2B) vs DHR (24.8B) and A (7.23B).
ADHRTMO
Capitalization39.1B135B211B
EBITDA1.96B7.08B11.7B
Gain YTD2.449-15.994-1.736
P/E Ratio27.8334.1430.58
Revenue7.23B24.8B45.2B
Total Cash1.81BN/A1.12B
Total Debt3.36B18.5B43.2B
FUNDAMENTALS RATINGS
A vs DHR vs TMO: Fundamental Ratings
A
DHR
TMO
OUTLOOK RATING
1..100
822033
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
6
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
10010080
SMR RATING
1..100
448062
PRICE GROWTH RATING
1..100
195140
P/E GROWTH RATING
1..100
567237
SEASONALITY SCORE
1..100
75n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DHR's Valuation (6) in the Medical Specialties industry is in the same range as A (10) in the Biotechnology industry, and is in the same range as TMO (12) in the Medical Specialties industry. This means that DHR's stock grew similarly to A’s and similarly to TMO’s over the last 12 months.

TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as DHR (100) in the Medical Specialties industry, and is in the same range as A (100) in the Biotechnology industry. This means that TMO's stock grew similarly to DHR’s and similarly to A’s over the last 12 months.

A's SMR Rating (44) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for DHR (80) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and somewhat faster than DHR’s over the last 12 months.

A's Price Growth Rating (19) in the Biotechnology industry is in the same range as TMO (40) in the Medical Specialties industry, and is in the same range as DHR (51) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and similarly to DHR’s over the last 12 months.

TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as A (56) in the Biotechnology industry, and is somewhat better than the same rating for DHR (72) in the Medical Specialties industry. This means that TMO's stock grew similarly to A’s and somewhat faster than DHR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADHRTMO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 3 days ago
54%
Bullish Trend 3 days ago
61%
Declines
ODDS (%)
Bearish Trend 6 days ago
64%
Bearish Trend 5 days ago
61%
Bearish Trend 5 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
63%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
A
Daily Signal:
Gain/Loss:
DHR
Daily Signal:
Gain/Loss:
TMO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AZO2957.4133.91
+1.16%
AutoZone
GSBD8.660.05
+0.58%
Goldman Sachs BDC
OTF9.950.02
+0.20%
Blue Owl Technology Fin Corp
WHG19.22N/A
N/A
Westwood Holdings Group
PETZ1.18-0.06
-4.84%
TDH Holdings

DHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DHR
1D Price
Change %
DHR100%
-0.52%
TMO - DHR
77%
Closely correlated
-0.71%
A - DHR
73%
Closely correlated
-0.84%
RGEN - DHR
68%
Closely correlated
-4.10%
BIO - DHR
64%
Loosely correlated
-0.61%
IQV - DHR
59%
Loosely correlated
+0.35%
More